These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38638303)

  • 1. 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy.
    Jiang S; Sydney EJ; Runyan AM; Serpe R; Srikanth M; Figueroa HY; Yang M; Myeku N
    Front Cell Neurosci; 2024; 18():1338502. PubMed ID: 38638303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy.
    Jiang S; Sydney EJ; Runyan AM; Serpe R; Figueroa HY; Yang M; Myeku N
    bioRxiv; 2023 Feb; ():. PubMed ID: 36778352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleep disruption precedes forebrain synaptic Tau burden and contributes to cognitive decline in a sex-dependent manner in the P301S Tau transgenic mouse model.
    Martin SC; Joyce KK; Harper KM; Nikolova VD; Cohen TJ; Moy SS; Diering GH
    bioRxiv; 2023 Jun; ():. PubMed ID: 37333395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
    Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
    J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Social and Psychological Stress Impact Select Neuropathologies in the PS19 Mouse Model of Tauopathy.
    Lyons CE; Graves SI; Razzoli M; Jeganathan K; Mansk RP; McGonigle S; Sabarinathan N; van Deursen JM; Baker DJ; Bartolomucci A
    Psychosom Med; 2024 Jun; 86(5):366-378. PubMed ID: 37910129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy.
    Brody AH; Nies SH; Guan F; Smith LM; Mukherjee B; Salazar SA; Lee S; Lam TKT; Strittmatter SM
    Mol Neurodegener; 2022 May; 17(1):32. PubMed ID: 35501917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.
    Schaler AW; Runyan AM; Clelland CL; Sydney EJ; Fowler SL; Figueroa HY; Shioda S; Santa-Maria I; Duff KE; Myeku N
    Sci Transl Med; 2021 May; 13(595):. PubMed ID: 34039738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic Spine Remodeling and Synaptic Tau Levels in PS19 Tauopathy Mice.
    Walker CK; Greathouse KM; Boros BD; Poovey EH; Clearman KR; Ramdas R; Muhammad HM; Herskowitz JH
    Neuroscience; 2021 Feb; 455():195-211. PubMed ID: 33346120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic stimulation of the serotonergic 5-HT4 receptor modulates amyloid-beta-related impairments in synaptic plasticity and memory deficits in male rats.
    Hashemi-Firouzi N; Shahidi S; Soleimani Asl S
    Brain Res; 2021 Dec; 1773():147701. PubMed ID: 34695393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.
    Makani V; Zhang B; Han H; Yao Y; Lassalas P; Lou K; Paterson I; Lee VM; Trojanowski JQ; Ballatore C; Smith AB; Brunden KR
    Acta Neuropathol Commun; 2016 Sep; 4(1):106. PubMed ID: 27687527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging-associated REGγ proteasome decline predisposes to tauopathy.
    Tu J; Zhang H; Yang T; Liu Y; Kibreab S; Zhang Y; Gao L; Moses RE; O'Malley BW; Xiao J; Li X
    J Biol Chem; 2022 Nov; 298(11):102571. PubMed ID: 36209822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration.
    Gratuze M; Leyns CE; Sauerbeck AD; St-Pierre MK; Xiong M; Kim N; Serrano JR; Tremblay MÈ; Kummer TT; Colonna M; Ulrich JD; Holtzman DM
    J Clin Invest; 2020 Sep; 130(9):4954-4968. PubMed ID: 32544086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice.
    Yukawa K; Yamamoto-Mcguire S; Cafaro L; Hong C; Kamme F; Ikezu T; Ikezu S
    Acta Neuropathol Commun; 2023 Oct; 11(1):166. PubMed ID: 37853497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatments with a 5-HT
    Baranger K; Giannoni P; Girard SD; Girot S; Gaven F; Stephan D; Migliorati M; Khrestchatisky M; Bockaert J; Marchetti-Gauthier E; Rivera S; Claeysen S; Roman FS
    Neuropharmacology; 2017 Nov; 126():128-141. PubMed ID: 28844596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.
    Hochgräfe K; Sydow A; Mandelkow EM
    FEBS J; 2013 Sep; 280(18):4371-81. PubMed ID: 23517246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APPsα Rescues Tau-Induced Synaptic Pathology.
    Bold CS; Baltissen D; Ludewig S; Back MK; Just J; Kilian L; Erdinger S; Banicevic M; Rehra L; Almouhanna F; Nigri M; Wolfer DP; Spilger R; Rohr K; Kann O; Buchholz CJ; von Engelhardt J; Korte M; Müller UC
    J Neurosci; 2022 Jul; 42(29):5782-5802. PubMed ID: 35667850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug, rescues learning behavior deficits in the PS19 MAPT
    Perez-Garcia G; Bicak M; Haure-Mirande JV; Perez GM; Otero-Pagan A; Gama Sosa MA; De Gasperi R; Sano M; Barlow C; Gage FH; Readhead B; Ehrlich ME; Gandy S; Elder GA
    Neurosci Lett; 2023 Feb; 797():137080. PubMed ID: 36657633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E isoform does not influence trans-synaptic spread of tau pathology in a mouse model.
    Davies C; Tulloch J; Yip E; Currie L; Colom-Cadena M; Wegmann S; Hyman BT; Wilkins L; Hooley M; Tzioras M; Spires-Jones TL
    Brain Neurosci Adv; 2023; 7():23982128231191046. PubMed ID: 37600228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Alterations in the Olfactory Neuronal Circuit Occur before Hippocampal Plasticity Deficits in the P301S Mouse Model of Tauopathy: Implications for Early Diagnosis and Translational Research in Alzheimer's Disease.
    Ahnaou A; Rodriguez-Manrique D; Biermans R; Embrechts S; Manyakov NV; Drinkenburg WH
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.